Phase I Study of LEE011plus Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ribociclib (Primary) ; Cetuximab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 08 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 23 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.